176 related articles for article (PubMed ID: 28012134)
1. Elevated levels of epithelial cell transforming sequence 2 predicts poor prognosis for prostate cancer.
Guo Z; Chen X; Du T; Zhu D; Lai Y; Dong W; Wu W; Lin C; Liu L; Huang H
Med Oncol; 2017 Jan; 34(1):13. PubMed ID: 28012134
[TBL] [Abstract][Full Text] [Related]
2. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
[TBL] [Abstract][Full Text] [Related]
3. Elevated expression of ECT2 predicts unfavorable prognosis in patients with colorectal cancer.
Luo Y; Qin SL; Mu YF; Wang ZS; Zhong M; Bian ZQ
Biomed Pharmacother; 2015 Jul; 73():135-9. PubMed ID: 26211594
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of ECT2 is associated with poor prognosis in gastric cancer patients.
Jin Y; Yu Y; Shao Q; Ma Y; Zhang R; Yao H; Xu Y
Int J Clin Exp Pathol; 2014; 7(12):8724-31. PubMed ID: 25674238
[TBL] [Abstract][Full Text] [Related]
5. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
6. Expression and prognostic significance of ECT2 in invasive breast cancer.
Wang HK; Liang JF; Zheng HX; Xiao H
J Clin Pathol; 2018 May; 71(5):442-445. PubMed ID: 29051317
[TBL] [Abstract][Full Text] [Related]
7. CPNE1 Is a Useful Prognostic Marker and Is Associated with TNF Receptor-Associated Factor 2 (TRAF2) Expression in Prostate Cancer.
Liang J; Zhang J; Ruan J; Mi Y; Hu Q; Wang Z; Wei B
Med Sci Monit; 2017 Nov; 23():5504-5514. PubMed ID: 29151113
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of microRNA-223/epithelial cell transforming sequence 2 signaling in patients with osteosarcoma.
Zhang H; Yin Z; Ning K; Wang L; Guo R; Ji Z
Hum Pathol; 2014 Jul; 45(7):1430-6. PubMed ID: 24784921
[TBL] [Abstract][Full Text] [Related]
9. High levels of glioma tumor suppressor candidate region gene 1 predicts a poor prognosis for prostate cancer.
Ma X; Du T; Zhu D; Chen X; Lai Y; Wu W; Wang Q; Lin C; Li Z; Liu L; Huang H
Oncol Lett; 2018 Nov; 16(5):6749-6755. PubMed ID: 30405818
[TBL] [Abstract][Full Text] [Related]
10. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
11. Elevated expression of PTCD3 correlates with tumor progression and predicts poor prognosis in patients with prostate cancer.
Huang Y; Jiang G; Liang X; Lan Z; Su Z; Wu H; Weng J; Jiang X
Mol Med Rep; 2018 Oct; 18(4):3914-3922. PubMed ID: 30132530
[TBL] [Abstract][Full Text] [Related]
12. Expression level of ECT2 proto-oncogene correlates with prognosis in glioma patients.
Sano M; Genkai N; Yajima N; Tsuchiya N; Homma J; Tanaka R; Miki T; Yamanaka R
Oncol Rep; 2006 Nov; 16(5):1093-8. PubMed ID: 17016598
[TBL] [Abstract][Full Text] [Related]
13. Role of Epithelial Cell Transforming Sequence 2 (ECT2) in Predicting Prognosis of Osteosarcoma.
Chen Z; Liu J; Zhang Y
Med Sci Monit; 2017 Aug; 23():3861-3868. PubMed ID: 28794404
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological and prognostic significance of epithelial cell transforming sequence 2 expression in cancers: a systematic review and meta-analysis.
Li B; Lin JP; Li Z; Yin C; Yang JB; Meng YQ
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4139-4148. PubMed ID: 31698961
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Mel-18 expression in prostate cancer tissues and correlation with clinicopathologic features.
Wang W; Lin T; Huang J; Hu W; Xu K; Liu J
Urol Oncol; 2011; 29(3):244-51. PubMed ID: 19395284
[TBL] [Abstract][Full Text] [Related]
16. Enhanced expression of SRPK2 contributes to aggressive progression and metastasis in prostate cancer.
Zhuo YJ; Liu ZZ; Wan S; Cai ZD; Xie JJ; Cai ZD; Song SD; Wan YP; Hua W; Zhong W; Wu CL
Biomed Pharmacother; 2018 Jun; 102():531-538. PubMed ID: 29587239
[TBL] [Abstract][Full Text] [Related]
17. A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival.
Huang TB; Dong CP; Zhou GC; Lu SM; Luan Y; Gu X; Liu L; Ding XF
Int Urol Nephrol; 2017 May; 49(5):825-835. PubMed ID: 28188414
[TBL] [Abstract][Full Text] [Related]
18. miR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma.
Xu S; Yi XM; Zhang ZY; Ge JP; Zhou WQ
Mol Med Rep; 2016 Dec; 14(6):5025-5032. PubMed ID: 27779679
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of Pleomorphic Adenoma Gene-Like 2 Is a Novel Poor Prognostic Marker of Prostate Cancer.
Guo J; Wang M; Wang Z; Liu X
PLoS One; 2016; 11(8):e0158667. PubMed ID: 27537362
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
